- Home
- HDL vs INVA Comparison
HDL vs INVA Comparison
Compare HDL & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- INVA
- Stock Information
- Founded
- HDL 2016
- INVA 1996
- Country
- HDL Singapore
- INVA United States
- Employees
- HDL N/A
- INVA N/A
- Industry
- HDL Restaurants
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- INVA Health Care
- Exchange
- HDL Nasdaq
- INVA Nasdaq
- Market Cap
- HDL 1.4B
- INVA 1.2B
- IPO Year
- HDL 2024
- INVA 2004
- Fundamental
- Price
- HDL $24.55
- INVA $18.28
- Analyst Decision
- HDL
- INVA Buy
- Analyst Count
- HDL 0
- INVA 1
- Target Price
- HDL N/A
- INVA N/A
- AVG Volume (30 Days)
- HDL 11.1K
- INVA 585.7K
- Earning Date
- HDL 02-20-2025
- INVA 02-27-2025
- Dividend Yield
- HDL N/A
- INVA N/A
- EPS Growth
- HDL N/A
- INVA 46.55
- EPS
- HDL 0.09
- INVA 0.99
- Revenue
- HDL $759,894,000.00
- INVA $352,745,000.00
- Revenue This Year
- HDL $18.96
- INVA $16.20
- Revenue Next Year
- HDL $14.25
- INVA N/A
- P/E Ratio
- HDL $272.51
- INVA $18.59
- Revenue Growth
- HDL 16.09
- INVA 21.46
- 52 Week Low
- HDL $13.94
- INVA $14.33
- 52 Week High
- HDL $30.00
- INVA $21.28
- Technical
- Relative Strength Index (RSI)
- HDL N/A
- INVA 50.49
- Support Level
- HDL N/A
- INVA $18.66
- Resistance Level
- HDL N/A
- INVA $19.06
- Average True Range (ATR)
- HDL 0.00
- INVA 0.35
- MACD
- HDL 0.00
- INVA 0.06
- Stochastic Oscillator
- HDL 0.00
- INVA 48.96
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.